Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 (esmethadone) as adjunctive therapy in MDD
NCT03051256Phase 2Completed
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- May 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esmethadone in major depressive disorder (MDD), sponsored by Relmada Therapeutics, Inc.. Started May 2018; status: completed.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03051256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051256.